Prostate cancer (CaP) is the most frequently diagnosed cancer and the second cause of cancer deaths in men in the US. Four potent anti-cancer activities have been ascribed to Vitamin D: 1) anti-proliferation, 2) anti-angiogenesis, 3) pro-apoptosis and 4) pro-differentiation. However, vitamin D also mobilizes calcium stores causing toxic hypercalcemic effects. New analogs have been developed that retain the anti-cancer activities of vitamin D but without the associated systemic toxicity. Our hypothesis is that vitamin D compounds, that retain anti-cancer properties but have reduced calcemic activity, can be used as a chemopreventive agent to prevent/slow the progression and metastatic spread of CaP. We propose 4 specific aims: I: To determine if calcitriol and two vitamin D analogs with low systemic toxicity (1LX23-7553 & QW1624F2-2) can prevent/slow carcinogenesis in an autochthonous model of CaP (TRAMP) and characterize the molecular effects of these compounds during prostate cancer progression. II: To determine if calcitriol and the less calcemic vitamin D compounds ILX23-7553 & QW1624F2-2 can prevent/slow the development and metastatic spread of androgen-independent CaP in castrated TRAMP animals and characterize the molecular effects of these compounds on androgen-independent disease. III: To identify key molecular pathways involved in vitamin D?s anti-cancer activity by comparing the molecular phenotype of tumor-derived cells from naive TRAMP tumors and vitamin D-resistant TRAMP tumors. IV: To evaluate the in vivo response of human CaP to ILX23-7553 by treating men with localized CaP prior to prostatectomy with ILX23-7553 and characterizing the molecular phenotype of the response. Effects of calcitriol, ILX23-7553 and QWI1624F2-2 treatment on proliferation, apoptosis, angiogenesis and differentiation will be studied in androgen-dependent and -independent CaP. Vitamin D resistant tumors will be induced in TRAMP and the molecular phenotype compared to naive TRAMP tumors. Finally a clinical trial examining the in vivo molecular response of organ confined human CaP to ILX23-7553 is proposed. These studies will provide preclinical data on the preventive activity of vitamin D compounds that can be used to design and initiate clinical trials using these compounds as a chemopreventive agent for human prostate cancer. These studies will identify key molecular pathways for vitamin D action that can be used to identify patients that are most/least likely to benefit from vitamin D therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA095367-02
Application #
6662006
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Kim, Young Shin
Project Start
2002-09-20
Project End
2006-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$403,467
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Battaglia, Sebastiano; Karasik, Ellen; Gillard, Bryan et al. (2017) LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer. Clin Epigenetics 9:82
Sabnis, Neha G; Miller, Austin; Titus, Mark A et al. (2017) The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Mol Cancer Res 15:128-140
Seedhouse, Steven J; Affronti, Hayley C; Karasik, Ellen et al. (2016) Metastatic phenotype in CWR22 prostate cancer xenograft following castration. Prostate 76:359-68
Gangavarapu, Kalyan J; Miller, Austin; Huss, Wendy J (2016) Gene Expression in Single Cells Isolated from the CWR-R1 Prostate Cancer Cell Line and Human Prostate Tissue Based on the Side Population Phenotype. Single Cell Biol 5:
Doig, Craig L; Battaglia, Sebastiano; Khanim, Farhat L et al. (2016) Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol 155:47-55
Long, Mark D; Sucheston-Campbell, Lara E; Campbell, Moray J (2015) Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol 230:758-66
Thorne, James L; Campbell, Moray J (2015) Nuclear receptors and the Warburg effect in cancer. Int J Cancer 137:1519-27
Singh, Prashant K; Long, Mark D; Battaglia, Sebastiano et al. (2015) VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription. Epigenetics 10:40-9
Long, Mark D; Campbell, Moray J (2015) Pan-cancer analyses of the nuclear receptor superfamily. Nucl Receptor Res 2:
Long, Mark D; van den Berg, Patrick R; Russell, James L et al. (2015) Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. Nucleic Acids Res 43:7330-48

Showing the most recent 10 out of 26 publications